Bexa & Early Detection
Dr. Monique Gary serves as Chief Medical Officer of Bexa, an innovative healthcare service company advancing early cancer detection through AI-enabled, radiation-free technologies.
Early detection remains one of the most powerful factors in improving outcomes. There is no treatment that can fully compensate for a cancer found too late.
Barriers to Access
Yet for many women, access, affordability, and experience remain significant barriers to screening. Confusing guidelines can exclude those at highest risk, while lack of consensus continues to erode trust in women’s health. Globally, the majority of women do not engage in regular early detection, often due to limited access or options they are willing to adopt.
A Growing Gap in Care
At the same time, emerging population health data points to a rising incidence of cancer among women younger than traditional screening thresholds. Many are diagnosed at later stages, often after detecting their own cancers, without having had access to accurate clinical breast evaluation during routine care.
Reimagining Early Detection
Dr. Gary’s work focuses on reimagining early detection as something expansive, not an alternative to convention. This means expanding access to screening that is accurate, accessible, painless, and designed around the whole person.
Adoption remains the number one missing component in early detection today. Creating an experience women will return to year after year is essential.
Early detection should feel like a routine part of wellness, not a series of anxiety-driven encounters.
As part of a broader commitment to precision wellness, this work extends beyond technology to include clinical, policy,
payor, and innovation ecosystems. Closing the women’s health gap is not only a clinical imperative, it is increasingly recognized as an economic one. Women spend significantly more of their lives in poor health, and expanding access to early detection and preventive care represents a meaningful opportunity to improve outcomes at both the individual and population level.
Early detection is not a single moment, but a continuous and essential component of care that has the potential to change outcomes for women and families across communities worldwide.
Learn More About Bexa
A New Kind of Breast Exam
Bexa is a new, FDA-cleared 510(k) medical device that employs high resolution elastography to produce a map of abnormal breast tissues and masses. A breast examination with Bexa is quick, painless, involves no radiation and provides women with an immediate result.
